Objective—To determine the effect of the 5α-reductase
inhibitor finasteride on prostatic diameter and
volume, semen quality, and serum dihydrotestosterone
(DHT) and testosterone concentrations in dogs
with spontaneous benign prostatic hypertrophy
Design—Double-blind placebo-controlled trial.
Animals—9 dogs with BPH.
Procedure—Five dogs were treated with finasteride
for 16 weeks (0.1 to 0.5 mg/kg [0.05 to 0.23 mg/lb] of
body weight, PO, q 24 h); the other 4 received a
placebo. Prostatic diameter, measured radiographically,
prostatic volume, measured ultrasonographically,
semen quality, and serum DHT and testosterone concentrations
were evaluated before and during treatment.
After receiving the placebo for 16 weeks, the 4
control dogs were treated with finasteride for 16
weeks, and evaluations were repeated.
Results—Finasteride significantly decreased prostatic
diameter (mean percentage decrease, 20%), prostatic
volume (mean percentage decrease, 43%),
and serum DHT concentration (mean percentage
decrease, 58%). Finasteride decreased semen volume
but did not adversely effect semen quality or
serum testosterone concentration. No adverse
effects were reported by owners of dogs in the
Conclusions and Clinical Relevance—Results suggest
that finasteride can be used to reduce prostatic
size in dogs with BPH without adversely affecting
semen quality or serum testosterone concentration.
(J Am Vet Med Assoc 2001;218:1275–1280)
Animals—20 client-owned dogs with osteoarthritis involving a single joint.
Procedures—Dogs were randomly assigned to a treatment or control group. In all dogs, severity of lameness and pain was scored by owners with the Hudson visual analog scale and the University of Pennsylvania Canine Brief Pain Inventory, respectively, and peak vertical force (PVF) was determined with a force platform. Dogs in the treatment group were then sedated, and a blood sample (55 mL) was obtained. Platelets were recovered by means of a point-of-use filter and injected intra-articularly within 30 minutes. Control dogs were sedated and given an intra-articular injection of saline (0.9% NaCl) solution. Assessments were repeated 12 weeks after injection of platelets or saline solution.
Results—Dogs weighed between 18.3 and 63.9 kg (40.3 and 140.6 lb) and ranged from 1.5 to 8 years old. For control dogs, lameness scores, pain scores, and PVF at week 12 were not significantly different from pretreatment values. In contrast, for dogs that received platelet injections, lameness scores (55% decrease in median score), pain scores (53% decrease in median score), and PVF (12% increase in mean PVF) were significantly improved after 12 weeks, compared with pretreatment values.
Conclusions and Clinical Relevance—Results suggested that a single intra-articular injection of autologous platelets resulted in significant improvements at 12 weeks in dogs with osteoarthritis involving a single joint.